Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

Isomorphic Labs, spun out from Google DeepMind in 2021, represents a growing trend of tech giants leveraging AI to streamline the traditionally lengthy and expensive drug development process.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Eli Lilly and ... and smart AI and digital technology, the group said in a Jan. 17 press release. Additionally, the initiative said it was committed to “onshoring” drug manufacturing in ...

Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly ...

Feb 5 (Reuters) - Eli Lilly (LLY.N), opens new tab investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...

Eli Lilly blamed the shortfall on lower-than-anticipated demand for its weight-loss drugs. Indeed, the drug maker estimated ... lies in the belief that some AI stocks hold greater promise for ...